Clinical Trial Update: Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

View source ↗

Summary

This clinical trial update outlines a head-to-head comparison of Opdualag versus Cemiplimab/Fianlimab in patients with unresectable or metastatic melanoma, asse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cemiplimab/Fianlimab (cemiplimab and fianlimab)
• Opdualag (relatlimab and nivolumab)

Snippet

Sponsor: John Kirkwood | Conditions: Locally Advanced Melanoma | Status: RECRUITING